CorMedix vs Evolus
CorMedix reported revenue of $312 million in fiscal 2025, about the same as Evolus' $297 million in fiscal 2025. CorMedix's revenue grew 617.0% in its latest year, and Evolus' grew 11.6%. CorMedix had an operating margin of 48.2%, against -11.0% at Evolus. Free cash flow was $173 million at CorMedix and −$46 million at Evolus.
Side by side
| CorMedix | Evolus | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $312M | $297M |
| Revenue growth | 617.0% | 11.6% |
| Revenue growth a year, last 5 years | 335.1% | 39.4% |
| Gross margin | 88.5% | 66.3% |
| Operating margin | 48.2% | −11.0% |
| Net margin | 52.3% | −17.4% |
| Free cash flow | $173M | −$46M |
| Free cash flow margin | 55.4% | −15.4% |
| Return on capital | — | −47.2% |
| Net debt to EBITDA | −0.9x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 36.4% | 4.0% |
| Last close | $4.66 | $6.96 |
| P/E at the last close | 7.8× | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CorMedixEvolus
Operating margin
Percent of revenue
CorMedixEvolus
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CorMedixEvolus